Cargando…

Ultra-early response assessment in lymphoma treatment: [(18)F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment

PURPOSE: To determine whether, in patients with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL), [(18)F]FDG PET/MR can capture treatment effects within the first week after treatment initiation, and whether changes in glucose metabolism and cell density occur simultaneously. METHODS: Patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayerhoefer, Marius E., Raderer, Markus, Jaeger, Ulrich, Staber, Philipp, Kiesewetter, Barbara, Senn, Daniela, Gallagher, Ferdia A., Brindle, Kevin, Porpaczy, Edit, Weber, Michael, Berzaczy, Dominik, Simonitsch-Klupp, Ingrid, Sillaber, Christian, Skrabs, Cathrin, Haug, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915494/ https://www.ncbi.nlm.nih.gov/pubmed/29480328 http://dx.doi.org/10.1007/s00259-018-3937-z

Ejemplares similares

RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2019)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study
por: Berzaczy, Dominik, et al.
Publicado: (2019)

First Line Systemic Treatment for MALT Lymphoma—Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Prolonged follow‐up on lenalidomide‐based treatment for mucosa‐associated lymphoid tissue lymphoma (MALT lymphoma)—Real‐world data from the Medical University of Vienna
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
por: Wagner, Sandro M., et al.
Publicado: (2020)

Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]Pentixafor: comparison with [(18)F]FDG-PET
por: Mayerhoefer, Marius E., et al.
Publicado: (2021)

18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging
por: Giraudo, Chiara, et al.
Publicado: (2016)

Treatment of mucosa associated lymphoid tissue lymphoma with a long‐term once‐weekly regimen of oral azithromycin: Results from the phase II MALT—A trial
por: Lagler, Heimo, et al.
Publicado: (2018)

Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging
por: Asenbaum, Ulrika, et al.
Publicado: (2016)

Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2017)

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study
por: Schiefer, Ana-Iris, et al.
Publicado: (2015)

Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
por: Mayerhoefer, Marius E., et al.
Publicado: (2016)

Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R: A case report
por: Porpaczy, Edit, et al.
Publicado: (2016)

CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication
por: Mayerhoefer, Marius E., et al.
Publicado: (2022)

Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients
por: Bilgilier, Ceren, et al.
Publicado: (2016)

The frequency of differentiated CD3(+)CD27(-)CD28(-) T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
por: Worel, Nina, et al.
Publicado: (2023)

Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?
por: Berzaczy, Dominik, et al.
Publicado: (2017)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
por: Kazianka, L, et al.
Publicado: (2017)

Clinical Features, Treatment and Outcome of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Ocular Adnexa: Single Center Experience of 60 Patients
por: Kiesewetter, Barbara, et al.
Publicado: (2014)

Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation
por: Freund, Patricia, et al.
Publicado: (2016)

Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna
por: Melhorn, Philipp, et al.
Publicado: (2022)

Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma
por: PORKERT, Stefanie, et al.
Publicado: (2021)

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
por: Kornauth, Christoph, et al.
Publicado: (2022)

Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI
por: Haug, Alexander R., et al.
Publicado: (2019)

The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies
por: Gaiger, Alexander, et al.
Publicado: (2022)

PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations
por: Mayerhoefer, Marius E., et al.
Publicado: (2019)

My burning issues in neuroendocrine tumours (NET)
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

How I treat MALT lymphoma: ‘a subjective interpretation of the gospel according to Isaacson….’
por: Raderer, Markus, et al.
Publicado: (2020)

How I treat neuroendocrine tumours
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

What you always wanted to know about gastric MALT-lymphoma: a focus on recent developments
por: Raderer, Markus, et al.
Publicado: (2021)

MRI and PET/MRI in hematologic malignancies
por: Mayerhoefer, Marius E., et al.
Publicado: (2019)

Cholecystectomy for acute cholecystitis. How time-critical are the so called “golden 72 hours”? Or better “golden 24 hours” and “silver 25–72 hour”? A case control study
por: Ambe, Peter, et al.
Publicado: (2014)

Infection with multidrug-resistant Campylobacter coli mimicking recurrence of carcinoid syndrome: a case report of a neuroendocrine tumor patient with repeated diarrhea
por: Lagler, Heimo, et al.
Publicado: (2016)

Management of adrenocortical carcinoma: are we making progress?
por: Kiesewetter, Barbara, et al.
Publicado: (2021)

Characteristics of an Unscheduled Emergency Department Revisit Within 72 hours of Discharge
por: Sah, Rajesh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jehmvj1m7tmbtt7prl3dkch8e7